Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Anja Hviid Simonsen, Sanna Kaisa Herukka, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B. Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G. Kramberger, Agnieszka Kulczyńska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O. Rinne, Uroš Rot & 8 others Esen Saka, Hilkka Soininen, Hanne Struyfs, Silvia Suardi, Pieter Jelle Visser, Bengt Winblad, Henrik Zetterberg, Gunhild Waldemar

Research output: Contribution to journalShort surveyAcademicpeer-review

Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1–42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

Original languageEnglish
Pages (from-to)274-284
Number of pages11
JournalAlzheimer's and Dementia
Volume13
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Cite this

Simonsen, A. H., Herukka, S. K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., ... Waldemar, G. (2017). Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 13(3), 274-284. https://doi.org/10.1016/j.jalz.2016.09.008
Simonsen, Anja Hviid ; Herukka, Sanna Kaisa ; Andreasen, Niels ; Baldeiras, Ines ; Bjerke, Maria ; Blennow, Kaj ; Engelborghs, Sebastiaan ; Frisoni, Giovanni B. ; Gabryelewicz, Tomasz ; Galluzzi, Samantha ; Handels, Ron ; Kramberger, Milica G. ; Kulczyńska, Agnieszka ; Molinuevo, Jose Luis ; Mroczko, Barbara ; Nordberg, Agneta ; Oliveira, Catarina Resende ; Otto, Markus ; Rinne, Juha O. ; Rot, Uroš ; Saka, Esen ; Soininen, Hilkka ; Struyfs, Hanne ; Suardi, Silvia ; Visser, Pieter Jelle ; Winblad, Bengt ; Zetterberg, Henrik ; Waldemar, Gunhild. / Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. In: Alzheimer's and Dementia. 2017 ; Vol. 13, No. 3. pp. 274-284.
@article{1e511f7e644f4e43aed2004b4b476e5c,
title = "Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia",
abstract = "This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1–42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.",
keywords = "Alzheimer's disease, Biomarkers, CSF, Diagnosis, GRADE, Recommendations",
author = "Simonsen, {Anja Hviid} and Herukka, {Sanna Kaisa} and Niels Andreasen and Ines Baldeiras and Maria Bjerke and Kaj Blennow and Sebastiaan Engelborghs and Frisoni, {Giovanni B.} and Tomasz Gabryelewicz and Samantha Galluzzi and Ron Handels and Kramberger, {Milica G.} and Agnieszka Kulczyńska and Molinuevo, {Jose Luis} and Barbara Mroczko and Agneta Nordberg and Oliveira, {Catarina Resende} and Markus Otto and Rinne, {Juha O.} and Uroš Rot and Esen Saka and Hilkka Soininen and Hanne Struyfs and Silvia Suardi and Visser, {Pieter Jelle} and Bengt Winblad and Henrik Zetterberg and Gunhild Waldemar",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.jalz.2016.09.008",
language = "English",
volume = "13",
pages = "274--284",
journal = "Alzheimers & Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "3",

}

Simonsen, AH, Herukka, SK, Andreasen, N, Baldeiras, I, Bjerke, M, Blennow, K, Engelborghs, S, Frisoni, GB, Gabryelewicz, T, Galluzzi, S, Handels, R, Kramberger, MG, Kulczyńska, A, Molinuevo, JL, Mroczko, B, Nordberg, A, Oliveira, CR, Otto, M, Rinne, JO, Rot, U, Saka, E, Soininen, H, Struyfs, H, Suardi, S, Visser, PJ, Winblad, B, Zetterberg, H & Waldemar, G 2017, 'Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia' Alzheimer's and Dementia, vol. 13, no. 3, pp. 274-284. https://doi.org/10.1016/j.jalz.2016.09.008

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. / Simonsen, Anja Hviid; Herukka, Sanna Kaisa; Andreasen, Niels; Baldeiras, Ines; Bjerke, Maria; Blennow, Kaj; Engelborghs, Sebastiaan; Frisoni, Giovanni B.; Gabryelewicz, Tomasz; Galluzzi, Samantha; Handels, Ron; Kramberger, Milica G.; Kulczyńska, Agnieszka; Molinuevo, Jose Luis; Mroczko, Barbara; Nordberg, Agneta; Oliveira, Catarina Resende; Otto, Markus; Rinne, Juha O.; Rot, Uroš; Saka, Esen; Soininen, Hilkka; Struyfs, Hanne; Suardi, Silvia; Visser, Pieter Jelle; Winblad, Bengt; Zetterberg, Henrik; Waldemar, Gunhild.

In: Alzheimer's and Dementia, Vol. 13, No. 3, 01.03.2017, p. 274-284.

Research output: Contribution to journalShort surveyAcademicpeer-review

TY - JOUR

T1 - Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

AU - Simonsen, Anja Hviid

AU - Herukka, Sanna Kaisa

AU - Andreasen, Niels

AU - Baldeiras, Ines

AU - Bjerke, Maria

AU - Blennow, Kaj

AU - Engelborghs, Sebastiaan

AU - Frisoni, Giovanni B.

AU - Gabryelewicz, Tomasz

AU - Galluzzi, Samantha

AU - Handels, Ron

AU - Kramberger, Milica G.

AU - Kulczyńska, Agnieszka

AU - Molinuevo, Jose Luis

AU - Mroczko, Barbara

AU - Nordberg, Agneta

AU - Oliveira, Catarina Resende

AU - Otto, Markus

AU - Rinne, Juha O.

AU - Rot, Uroš

AU - Saka, Esen

AU - Soininen, Hilkka

AU - Struyfs, Hanne

AU - Suardi, Silvia

AU - Visser, Pieter Jelle

AU - Winblad, Bengt

AU - Zetterberg, Henrik

AU - Waldemar, Gunhild

PY - 2017/3/1

Y1 - 2017/3/1

N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1–42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1–42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

KW - Alzheimer's disease

KW - Biomarkers

KW - CSF

KW - Diagnosis

KW - GRADE

KW - Recommendations

UR - http://www.scopus.com/inward/record.url?scp=85007289521&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.09.008

DO - 10.1016/j.jalz.2016.09.008

M3 - Short survey

VL - 13

SP - 274

EP - 284

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

IS - 3

ER -

Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia. 2017 Mar 1;13(3):274-284. https://doi.org/10.1016/j.jalz.2016.09.008